In what the companies said was an alliance seeking “increased profit for both companies,” Eisai Co. Ltd. is gradually to transfer full ownership of its Elmed Eisai generics business in Japan to Nichi-Iko Pharmaceutical Co. Ltd., one of the country’s largest generics concerns.
The move seeks to build on the assets and strengths of both firms in their respective sectors, and will involve...







